Cognizant Forges $800 Mn Partnership With Gilead Sciences Forge

Cognizant on Monday said it has renewed and expanded its collaboration with Gilead Sciences, a prominent biopharmaceutical company. The renewed partnership comes with a significant expected value of USD 800 million over the next five years.

Over the past three years, the two companies have worked together to leverage cutting-edge technologies that have seemingly resulted in improved business outcomes for Gilead.

The focus of this collaboration is to streamline various aspects of Gilead's business, with the ultimate goal of reducing the time it takes to bring essential medicines to market. The diseases in the spotlight include HIV, viral hepatitis, and cancer, which continue to pose significant challenges to global healthcare.

As part of the expanded partnership, Cognizant plans to harness the power of Generative AI (GenAI) and AI automation to enhance Gilead's customer service experience and drive manufacturing efficiencies. With the aid of GenAI, Gilead will gain better visibility and transparency in communicating treatment options to patients and employees worldwide. This innovative technology is expected to provide valuable insights and support in the development of crucial life-saving drugs.

To further bolster Gilead's capabilities, the biopharmaceutical giant will leverage Cognizant's Neuro IT service, a cutting-edge platform for AI automation innovation. This integration aims to expedite the process of bringing new products to the market efficiently and help reach more patients in need of life-saving medications.

In addition to adopting advanced AI technologies, Cognizant will collaborate with Gilead to develop and operate a range of applications and services that introduce new or enhanced technologies. These capabilities will enable Gilead to establish more efficient and differentiated business processes, ultimately contributing to a faster time-to-market for their life-saving medicines.